U.S. Markets closed

Novan, Inc. (NOVN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6125-0.0075 (-1.21%)
At close: 4:00PM EDT

0.6130 0.00 (0.08%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6200
Open0.6106
Bid0.6130 x 1100
Ask0.6147 x 900
Day's Range0.5946 - 0.6200
52 Week Range0.2150 - 3.7200
Volume9,763,159
Avg. Volume28,451,132
Market Cap78.536M
Beta (5Y Monthly)-0.26
PE Ratio (TTM)N/A
EPS (TTM)-1.0400
Earnings DateMay 19, 2020 - May 20, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
  • NOVN: R&D Update for Molluscum
    Zacks Small Cap Research

    NOVN: R&D Update for Molluscum

    By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT On July 14, 2020, Verrica Pharmaceutical (VRCA) announced that it had received a Complete Response Letter (CRL) from the FDA for its VP-102 (YCANTH) new drug application (NDA), which was submitted last September. Verrica had completed Phase III CAMP-1 and CAMP-2 pivotal trials which demonstrated safety and efficacy of the

  • GlobeNewswire

    Novan President and CEO, Paula Brown Stafford Named Chairman of the Board

    * Expanded role of Ms. Stafford as Chairman reflects the Board’s confidence in her leadership of the Company and strategic direction * Renowned pharmaceutical executive Robert Ingram retiring as Executive Chair and remaining a member of Board of Directors   MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief Executive Officer (“CEO”) of Novan, to also include Chairman of Novan’s Board of Directors (“Board”). Concurrently, Robert Ingram is retiring as Executive Chairman and will continue as a member of the Board. These changes to the Board are effective as of today, July 28, 2020.“Since Paula’s appointment as President and CEO of Novan, she has done a tremendous job leading the Company on multiple fronts, including securing the necessary capital to advance the upcoming B-SIMPLE4 pivotal trial, a major inflection point for the Company. She has a clear strategic vision, has demonstrated solid execution, and I believe will propel the Company forward through the next stage of growth. Having been a member of the Novan Board for nearly a decade, I along with my fellow Board members, felt strongly it was appropriate for Paula to assume the role of Chairman as she continues to lead and build momentum. Moving forward, I am pleased to remain a member of the Board and participate in the great strides and many opportunities we expect for the future,” commented Mr. Ingram.Ms. Stafford has been a member of the Board since August 2017 and has served as the Company’s President and CEO since February 2020, after holding various executive roles including Chief Operating Officer and Chief Development Officer since joining Novan in March 2017.“On behalf of the Board of Directors, we would like to sincerely thank Bob for his above and beyond contributions and valuable insights while serving as our Executive Chairman since 2016,” added Ms. Stafford. “His expertise in the industry, multitude of business relationships and wise judgment have been instrumental in guiding Novan through many business, developmental and financing milestones. I look forward to continuing to work closely with Bob as a member of our Board.”About Robert A. IngramMr. Robert A. Ingram is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of GlaxoWellcome. Upon reaching the mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram is Chairman of the Board of BioCryst Pharmaceuticals and recently retired as the Chairman of the Board of Cree, Inc. In 2019, Mr. Ingram was appointed by President Donald J. Trump’s administration to serve on the Presidential Cancer Panel.About NovanNovan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatology, women’s health and gastrointestinal diseases. Forward-Looking StatementsThis press release contains forward-looking statements including, but not limited to, statements related to our next phase of business progress. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, potential for delays and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that our product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that we may not obtain funding sufficient to complete the regulatory or development process; our ability to retain key personnel; our ability to obtain additional funding or enter into strategic relationships or other business development necessary for the further development of our product candidates; and other risks and uncertainties described in our annual report filed with the SEC on Form 10-K for the twelve months ended December 31, 2019, as amended, and in our subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.INVESTOR AND MEDIA CONTACT:  Jenene Thomas 833-475-8247 NOVN@jtcir.com   JTC Team, LLC

  • GlobeNewswire

    Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders

    MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annual Meeting of Stockholders ("ASM") on Tuesday, July 28, 2020 at 9:30 a.m. Eastern Time. Considering the coronavirus (COVID-19) pandemic, for the safety and health of Novan’s stockholders, employees and the broader community, the Company has determined that its 2020 Annual Meeting will be held solely via the Internet. To be admitted to the 2020 ASM webcast, stockholders need to visit www.virtualshareholdermeeting.com/NOVN2020 and enter the control number included on the proxy form or voting instruction form, as applicable. During the virtual annual meeting, stockholders of record as of June 11, 2020 will be able to vote their shares electronically and will be able to ask questions via the web portal, as time permits.Guests may listen to the 2020 ASM by visiting www.virtualshareholdermeeting.com/NOVN2020 and completing the guest login section of the web portal. If you are not a stockholder of record, you may still access and listen to the meeting, however, guests will be unable to submit questions during the webcast.Online check-in will begin 15 minutes prior, at 9:15 a.m. ET. The ASM will begin promptly at 9:30 a.m. ET on July 28, 2020.About NovanNovan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatology, women’s health and gastrointestinal diseases.Forward-Looking StatementsThis press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates and our intention to advance development of certain product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, potential for delays and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that our product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that we may not obtain funding sufficient to complete the regulatory or development process; our ability to obtain additional funding or enter into strategic or other business relationships necessary or useful for the further development of our product candidates; and other risks and uncertainties described in our annual report filed with the SEC on Form 10-K for the twelve months ended December 31, 2019, and in our subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.INVESTOR AND MEDIA CONTACT:Jenene Thomas JTC Team, LLC 833-475-8247 NOVN@jtcir.com